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Background: Venous thrombosis is a serious complication of combined contraceptive usage. 
However, mesenteric venous thrombosis and intestinal necrosis are infrequently seen in women 
using oral contraceptives, and in such cases diagnosis is often delayed.
Case presentation: We report the case of a 38-year-old obese female patient who presented 
with acute abdominal pain. A bowel infection was first diagnosed and treated with antibiotics. 
Contrast-enhanced tomography of the abdomen revealed diffuse ischemia of the small  intestine 
with superior mesenteric thrombosis. Laparotomy with segmental resection of both small and 
large bowel was performed. No predisposing factor of mesenteric venous thrombosis was dem-
onstrated except association of the combined contraceptive with obesity.
Conclusion: This report highlights the need for clinicians to suspect venous mesenteric throm-
bosis in women of reproductive age with acute abdominal pain and poor physical  findings. 
Detailed personal history including prescriptions should help to quickly and accurately  determine 
the problem.
Keywords: hormonal contraceptive, deep venous thrombosis, superior mesenteric vein, obesity, 
bowel infection
Introduction
Venous thrombosis is the result of stagnation of blood flow, vascular injury, and 
hypercoagulability (ie, Virchow’s triad). The risk of venous thrombosis associ-
ated with the estrogen component of combined hormonal contraceptives has been 
reported and debated since the 1960s. Hormonal contraceptives affect a large num-
ber of hemostatic variables: ethinylestradiol induces a rise in factor VII activity, 
prothrombin fragment 1+2, and resistance to the anticoagulant action of activated 
protein C.1 The prothrombotic effect of the estrogen component ethinylestradiol in 
combined contraceptives is influenced by the progestogen component present in these 
preparations.
Venous thromboembolism, although rare, remains one of the serious adverse con-
sequences of hormonal contraception. Most venous thrombotic events secondary to 
contraceptives usually manifest as deep vein leg thrombosis and pulmonary embolism. 
Pelvic, cerebral, and retinal veins are infrequent sites of thrombosis.
We report a case of superior mesenteric vein thrombosis (MVT) associated with 
the use of combined hormonal contraceptives. This led to diffuse ischemia of the 
small intestine.
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A 38-year-old nulliparous obese female patient consulted her 
general practioner for diffuse abdominal pain with fever. A 
bowel infection was diagnosed. She went back home with 
an antibiotic prescription. The treatment did not improve the 
symptoms. Two weeks later, she presented to the emergency 
department of the regional hospital with acute abdominal 
pain without nausea or vomiting. She had a body mass index 
(BMI) of 43 kg/m2 and smoked five cigarettes per day. She 
had stopped hormonal contraception 5 years ago. She had 
some combined oral contraceptive (COC) tablets (20 µg 
ethinylestradiol + gestodene) left at home and had decided 
to restart contraception 4 months ago without consulting her 
general practitioner or gynecologist. She had no personal or 
familial history of thrombosis. She had no previous medi-
cal condition and was not on any medication except her pill. 
On physical examination, she was afebrile and had diffuse 
abdominal pain with peritoneal signs. Laboratory examina-
tion showed increased C-reactive protein level of 102.5 mg/L 
(normal range, <5.0 mg/L) and LDH level of 370 U/L (normal 
range, 125–243 U/L). A computerized tomographic scan with 
intravenous contrast of the abdomen was performed. An acute 
venous mesenteric thrombosis with diffuse ischemia of the 
small intestine was identified.
The patient was anticoagulated with intravenous heparin. 
A laparotomy was performed which revealed small intestine 
ischemic necrosis and a mass on the transverse large bowel. A 
resection of 2 m of small intestine was performed, followed 
by temporary ileostomy as well as transverse colectomy with 
end-to-end anastomosis. Reanastomosis of the small intestine 
was performed 1 month later. At histopathologic examina-
tion of the large transverse bowel mass, acute inflammatory 
and fibrotic subserosal changes were observed. COC was 
stopped at the time of admission. Medroxyprogesterone 
acetate injection was given 1 month later at the time of small 
intestine reanastomosis, and the patient was switched to oral 
progestin 3 months later. Evaluation for prothrombotic condi-
tions including protein C, protein S, antithrombin deficiency; 
factor V, prothrombin gene mutation, lupus anticoagulant, 
and antiphospholipid and anticardiolipin antibodies were all 
negative. The patient gave written informed consent for her 
data to be used in this publication.
Discussion
Epidemiological studies indicate that venous thrombo-
embolism rates in noncontraceptive users of reproduc-
tive age approximate one per 10,000 women-years in 
20-year-old women, and five per 10,000 in women of 
40 years; rates in oral contraceptive users are in the range 
of 4–12/10,000 women per year.2 In comparison, venous 
thromboembolism rates in pregnancy approach 29/10,000 
overall and may reach 300–400/10,000 in the immediate 
postpartum period.3
The superior mesenteric vein is a rare site of thrombosis. 
MVT almost always involves the distal small intestine ileum 
or jejunum (superior mesenteric venous drainage) and rarely 
involves the colon (inferior mesenteric venous drainage). The 
inferior mesenteric venous distribution is less commonly 
involved – this is possibly related to collateral flow. Acute 
thrombotic occlusion of one or more mesenteric veins reduces 
perfusion pressure. If the venous arcades and vasa recta are 
involved and if the venous return from the bowel wall is com-
pletely occluded, bowel infarction will occur. Direct injury 
(trauma, surgery, pancreatitis, etc), local venous congestion 
(portal hypertension/cirrhosis of the liver, congestive heart 
failure, hypersplenism), and hypercoagulability caused by 
thrombophilia or malignancy are also risk factors for MVT. 
Incidence of MVT is estimated to be 2.7 per 100,000, and 
COC-related MVT accounts for 4%–5% of total MVT.4 
Superior MTV associated with hormonal contraception was 
first described in 1963, 3 years after the approval of the first 
oral contraceptive pill in the United States.5 Diagnosis is 
sometimes difficult because of nonspecific abdominal symp-
toms and physical examination, and delayed diagnosis causes 
extensive intestinal ischemia with a high risk of mortality. 
Prompt recognition is important because early systemic anti-
coagulation therapy may limit progression of the thrombotic 
process and allow nonoperative management. Diagnosis 
should be suspected when acute abdominal symptoms are 
disproportional to the physical findings. Detailed past medi-
cal or familial history of thrombosis and prescriptions used 
should be taken. Contrast-enhanced abdominal computerized 
tomography facilitates diagnosis and is considered as a gold 
standard.6 It can accurately detect portal vein, ovarian vein, 
and MVTs.
The treatment is predominantly conservative with sys-
temic anticoagulation. Surgical exploration is limited to 
patients with signs of bowel infarction. Discontinuation of 
COC is mandatory. Full hypercoagulability screening should 
be performed.
In the WHO Medical Eligibility criteria,7 obesity is not 
considered as a limiting factor for using COC. However, in 
recent data, the risk of venous thrombosis has been shown 
to be increased in COC users with morbid obesity in com-
parison with normal-weight contraceptive users, and the risk 
continues to increase with increasing BMI.8 It is important to 
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consider this increased risk with obesity when recommending 
a contraceptive method.
In the case described here, the patient decided to reuse 
COC without any health professional’s advice. As unin-
tended pregnancy in obese women leads to increased health 
risk, use of progestin contraception or intrauterine device is 
recommended. These methods do not expose the woman to 
potential risk associated with estrogen-containing contracep-
tives. Although venous thrombosis may occur at any time, 
thrombotic risk is maximal during the first 12 months of using 
or reusing COCs, and this is attributed to exposure to a new 
risk factor, especially if other risk factors are also present, 
such as in this case, age, morbid obesity, and smoking. The 
risks of hormonal preparations related to venous thrombosis 
disappear when COC is discontinued.9
Conclusion
Intestinal ischemia and necrosis caused by mesenteric 
venous thrombosis is a rare complication of combined con-
traceptives. Clinicians should consider intestinal ischemia in 
women on COC developing sudden severe abdominal pain 
without any other obvious cause of pathology.
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